Clinical trials: Newly Diagnosed Multiple Myeloma
Newly Diagnosed, Multiple Myeloma
Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma
In multiple myeloma, combination chemotherapy with melphalan plus prednisone has been usedsince the 1960s and is regarded as the standard of care in very elderly patients.
- Trial name
- IFM 01/01 (NCT00644306)
- Testing
- Thalidomide, melphalan, prednisone, melphalan, prednisone, thalidomide
- Where
- France
- Volunteers
- 232 people
- Sponsor
- Central Hospital, Nancy, France
Multiple Myeloma
Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)
This is a phase III, multicenter, prospective with a clinical benefit, open-label and randomized study to compare two different treatments : Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) versus Velcade (Bortezomib)…
- Trial name
- IFM2013-04 (NCT01971658)
- Testing
- Thalidomide®, Cyclophosphamide, Velcade®
- Where
- 62 sites in France
- Volunteers
- 358 people
- Sponsor
- Nantes University Hospital
Multiple Myeloma and Plasma Cell Neoplasm
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00033332
- Testing
- dexamethasone, pamidronate disodium, thalidomide
- Where
- 78 sites in United States, Puerto Rico and 1 more
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients
The aim of this non-interventional study is to collect primarily the percentage of patients who receive the full dose of dexamethasone (20 or 40 mg orally once daily on days 1, 8, 15 and 22 of the repetitive 28-day cycles, 20 mg…
- Trial name
- NCT03001804
- Where
- 12 sites in Austria
- Volunteers
- 29 people
- Sponsor
- Celgene
Multiple Myeloma
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)
The purpose of this study is to determine the effects that Elranatamab in combination with Lenalidomide and Dexamethasone has on participants that have been newly diagnosed with Multiple Myeloma.
- Trial name
- NCT06997081
- Testing
- Lenalidomide, Dexamethasone, Elranatamab
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- University of Miami
Multiple Myeloma
Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients
The is a randomized control study for newly-diagnosed myeloma patients 18-65 year old. All patients will receive 4 cycles of velcade and Dexamethasone as front-line therapy.
- Trial name
- NCT00984828
- Testing
- velcade
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Recurrent Plasma Cell Myeloma, Plasma Cell Myeloma
Copper 64Cu-DOTA-Daratumumab Positron Emission Tomography in Diagnosing Patients With Relapsed Multiple Myeloma
This pilot phase I clinical trial studies how well copper 64Cu-DOTA-daratumumab positron emission tomography works in diagnosing patients with multiple myeloma that has come back.
- Conditions
- Recurrent Plasma Cell Myeloma, Plasma Cell Myeloma, Secondary Amyloidosis
- Trial name
- NCT03311828
- Testing
- Daratumumab, Imaging Agent, Positron Emission Tomography
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma
The purpose of this study is to improve efficacy of treatment for patients with newly diagnosed multiple myeloma who are not eligible for high-dose chemotherapy followed by autologous stem cell transplantation by Bendamustin…
- Trial name
- BPV (NCT02237261)
- Testing
- Bendamustine, Bortezomib, Prednisone
- Where
- 15 sites in Germany
- Volunteers
- 46 people
- Sponsor
- University Hospital Heidelberg
Multiple Myeloma
A Trial Comparing Ramantamig and Daratumumab (Ramantamig-D) Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible
The purpose of this study is to compare how well Ramantamig plus Daratumumab (ramantamig-D) works compared with a treatment that includes Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd), followed by high-dose…
- Trial name
- TRIlogy-6 (NCT07903272)
- Testing
- Ramantamig, Daratumumab, Bortezomib
- Volunteers
- 1,000 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma, Venous Thromboembolism
Thrombosis in Patients With Multiple Myeloma in an University Medical Center
Main research question: What is the present venous thrombosis incidence and what are the current practices of prescribing thromboprophylaxis in patients with multiple myeloma (MM)? Design: The present study is a retrospective…
- Conditions
- Multiple Myeloma, Venous Thromboembolism, Arterial Thromboembolism
- Trial name
- THRIMM (NCT05541978)
- Testing
- Multiple myeloma
- Where
- Netherlands
- Volunteers
- 140 people
- Sponsor
- Catalina Codreanu
Multiple Myeloma and Plasma Cell Neoplasm
Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by…
- Trial name
- NCT00317811
- Testing
- ascorbic acid, bortezomib, melphalan
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- Oncotherapeutics
Multiple Myeloma
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Multiple myeloma (MM) is a cancer of the blood's plasma cells. The cancer is typically found in the bones and bone marrow (the spongy tissue inside of the bones) and can cause bone pain, fractures, infections, weaker bones, and…
- Trial name
- NCT07095452
- Testing
- Etentamig, Lenalidomide, Daratumumab
- Where
- 49 sites in United States, France and 2 more
- Volunteers
- 680 people
- Sponsor
- AbbVie
Multiple Myeloma
Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma
Study Objectives 1. Evaluate the efficacy of the combination of thalidomide (Thalomid®), clarithromycin (Biaxin®), lenalidomide (Revlimid®), and dexamethasone (Decadron®) as an induction therapy for patients with newly diagnosed…
- Trial name
- T-BiRD (NCT00538733)
- Testing
- thalomid, lenalidomide, clarithromycin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Weill Medical College of Cornell University
Multiple Myeloma
Sequential Therapy in Multiple Myeloma Guided by MRD Assessments
This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment.
- Trial name
- MASTER-2 (NCT05231629)
- Testing
- Dara-VRd intensification, Dara-R maintenance, AHCT intensification, Dara-R maintenance, AHCT intensification, Tec-Dara consolidation, Tec-Dara maintenance
- Where
- 10 sites in United States
- Volunteers
- 300 people
- Sponsor
- University of Alabama at Birmingham
Myeloma, Plasma-Cell, Myeloma-Multiple
Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma
Background: Cancer development is associated with problems in immune system functions, which prevent the body from attacking and destroying the abnormal cells that lead to tumor growth.
- Conditions
- Myeloma, Plasma-Cell, Myeloma-Multiple, Myelomatosis
- Trial name
- NCT01239368
- Testing
- Adoptive Immunotherapy, Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells), Th1/Tc1 Rapa Cell Therapy
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, New Diagnosis Tumor
A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant
The combination of lenalidomide plus low-dose dexamethasone (Rd) is considered the new standard for elderly newly diagnosed multiple myeloma (NDMM) patients.
- Trial name
- KRdvsRd (NCT04096066)
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone
- Where
- 40 sites in Italy
- Volunteers
- 84 people
- Sponsor
- Fondazione EMN Italy Onlus
Multiple Myeloma, Hematopoietic Stem Cell Mobilization
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients
This is a prospective, randomized, two-arm, multicenter, exploratory study aimed at evaluating the efficacy and safety of the combination of etoposide, cytarabine and Pegfilgrastim (EAP regimen) for mobilizing hematopoietic stem…
- Trial name
- NCT06520176
- Testing
- Etoposide, Cytarabine, Pegfilgrastim
- Where
- 16 sites in China
- Volunteers
- 99 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Multiple Myeloma
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
- Trial name
- MagnetisMM-6 (NCT05623020)
- Testing
- Elranatamab, Daratumumab, Lenalidomide
- Where
- 180 sites in United States, Argentina and 23 more
- Volunteers
- 1,060 people
- Sponsor
- Pfizer
Multiple Myeloma
Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients
The purpose of this study is to determine whether the association of Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) as induction treatment is safe and provides benefits in patients with newly diagnosed Multiple Myeloma…
- Trial name
- CCD (NCT01346787)
- Testing
- CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE
- Where
- 13 sites in Italy, Netherlands
- Volunteers
- 58 people
- Sponsor
- European Myeloma Network B.V.
Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma Patients Ineligible or Unwilling to Undergo ASCT, Newly Diagnosed Multiple Myeloma (NDMM)
RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma
This is a single-arm, dose-escalation exploratory study evaluating the safety and efficacy of RN1201, a BCMA/CD19-targeted allogeneic CAR-T cell therapy, in patients with newly diagnosed cytogenetically high-risk multiple myeloma…
- Trial name
- NCT07114432
- Testing
- BCMA/CD19-targeted allogeneic CAR-T
- Where
- 2 sites in China
- Volunteers
- 19 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital